Previous studies focused on the prognostic role of tumor mutational burden (TMB) in immunotherapy in many cancer types; here, we counted the TMB of each tumor sample and analyzed the relationship between PDLIM2 expression and TMB in 12 different cancer types. Here, PDLIM2 is linked to neoplasm.